Our observations that TM4SF5 promoted HCC in different in-vivo models by downregulating Slamf7 levels and NK cell cytotoxicity suggest that anti-TM4SF5 isoxazoles act as NK cell immune-checkpoint inhibitors (ICIs). This evidence concerns the gene TM4SF5 and hepatocellular carcinoma.